You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR IODIXANOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for iodixanol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00209404 ↗ Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA) Completed GE Healthcare Phase 4 2005-07-01 Image quality in coronary artery computed tomography is influenced by the heart rate variation during the examination. The purpose of this clinical trial is to investigate the change in heart rate following injection of a contrast medium called Visipaqueâ„¢ (iodixanol). Image quality and diagnostic quality of the examination will be evaluated.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated ABX CRO Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated ABX-CRO Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated Averion International Corporation Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for iodixanol

Condition Name

Condition Name for iodixanol
Intervention Trials
Coronary Artery Disease 6
Coronary Artery Stenosis 3
Kidney Failure, Chronic 3
Diabetes Mellitus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for iodixanol
Intervention Trials
Renal Insufficiency 10
Coronary Artery Disease 7
Myocardial Ischemia 6
Renal Insufficiency, Chronic 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for iodixanol

Trials by Country

Trials by Country for iodixanol
Location Trials
United States 44
China 22
Canada 3
United Kingdom 3
Korea, Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for iodixanol
Location Trials
New Jersey 9
California 4
New York 3
Illinois 3
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for iodixanol

Clinical Trial Phase

Clinical Trial Phase for iodixanol
Clinical Trial Phase Trials
Phase 4 23
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for iodixanol
Clinical Trial Phase Trials
Completed 20
Terminated 11
Not yet recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for iodixanol

Sponsor Name

Sponsor Name for iodixanol
Sponsor Trials
GE Healthcare 10
Bracco Diagnostics, Inc 5
i3 Statprobe 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for iodixanol
Sponsor Trials
Other 34
Industry 30
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.